Insights and Analysis
AI-washing – when AI hype becomes a litigation risk
Hogan Lovells Events
The Supreme Court’s Loper Bright and Corner Post decisions—what now for pharma?
In two decisions issued at the end of the 2023 Supreme Court term, the Court overruled the 40-year-old Chevron doctrine, which required courts to defer to agencies’ reasonable interpretations of ambiguous or silent statutes (Loper Bright); and extended the window to challenge certain agency actions in certain circumstances (Corner Post).
In this program, we’ll discuss what is and isn’t a Loper Bright issue; how industry can and should play offense and defense following the Court’s decisions; and some areas that may—and may not—be ripe for reconsideration following Loper Bright and Corner Post.
Register here
Contacts
Washington, D.C.
View more insights and analysis
